RPS6KB2

Across TCGA pan-cancer cohorts, RPS6KB2 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of RPS6KB2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where RPS6KB2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RPS6KB2 is over-expressed in tumor.

KIRC, COAD, and LUAD are the cancer types where RPS6KB2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPS6KB2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+0.821	<.001	12	view →
COAD	Female	All	+0.821	<.001	10	view →
LUAD	All	III,IV	+0.644	<.001	9	view →
LIHC	Female	II,III,IV	+0.937	<.001	8	view →
BLCA	Male	III,IV	+0.912	<.001	8	view →
BRCA	All	III,IV	+0.698	<.001	8	view →
LUSC	Male	II,III,IV	+0.799	<.001	7	view →
UCEC	All	All	+0.703	<.001	6	view →
STAD	All	II,III,IV	+0.576	.003	4	view →
KIRP	Female	All	+0.402	.008	4	view →
CHOL	Female	All	+1.716	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

RPS6KB2–KIRC

Open the KIRC breakdown →